TriSalus Life Sciences (NASDAQ:TLSI) Cut to Sell at Wall Street Zen

by · The Markets Daily

Wall Street Zen lowered shares of TriSalus Life Sciences (NASDAQ:TLSI – Free Report) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

A number of other analysts have also recently commented on TLSI. Zacks Research upgraded shares of TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, December 16th. Canaccord Genuity Group increased their price objective on TriSalus Life Sciences from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $11.00.

Check Out Our Latest Analysis on TriSalus Life Sciences

TriSalus Life Sciences Stock Down 10.1%

Shares of NASDAQ:TLSI opened at $5.53 on Friday. The company has a market cap of $276.28 million, a price-to-earnings ratio of -2.74 and a beta of 0.43. TriSalus Life Sciences has a twelve month low of $3.42 and a twelve month high of $7.95. The business has a 50 day moving average price of $6.26 and a 200 day moving average price of $5.24.

TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.79). The business had revenue of $11.57 million for the quarter, compared to analysts’ expectations of $11.76 million. Analysts anticipate that TriSalus Life Sciences will post -1.55 EPS for the current year.

Hedge Funds Weigh In On TriSalus Life Sciences

Several large investors have recently modified their holdings of TLSI. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of TriSalus Life Sciences in the second quarter worth about $29,000. JPMorgan Chase & Co. grew its holdings in shares of TriSalus Life Sciences by 35,804.8% in the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after purchasing an additional 7,519 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in TriSalus Life Sciences during the 2nd quarter valued at approximately $47,000. Sequoia Financial Advisors LLC bought a new stake in shares of TriSalus Life Sciences during the third quarter valued at approximately $90,000. Finally, New York State Common Retirement Fund purchased a new position in TriSalus Life Sciences in the second quarter worth about $108,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

(Get Free Report)

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.

Featured Articles